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Introduction 
INTRODUCTION 
 HIV has indeed turned into on global pandemic. In India 
alone the problem is waiting to explode what with an estimated 
population of about 5,700,000 infected with HIV1.  An 
estimated 6 million cases will be infected with HIV by year 
20102.  This issue is important since we are seeing patients 
infected with the disease almost on a daily basis and these 
patients are subjected to various invasive procedures.  
 It has been well documented that HIV infection is 
associated with Autonomic Dysfunction3,4. 
 Cardiovascular Autonomic dysfunction has been 
demonstrated to severely debilitated HIV infection patients3,4,6 
and may also be associated with life threatening cardio 
respiratory arrest following invasive diagnostic procedure5. 
 Despite the possible significance of this findings and the 
suggestion by others of autonomic dysfunction in HIV infection, 
little research has been undertaken on this topic, specifically in 
the Indian subcontinent.  
 A higher prevalence of QT prolongation has been reported 
in HIV/ AIDS patients and also the cause of the sudden death 
in HIV is ascribed to QT prolongation with risk for ventricular 
arrhythmias7,8.  Most of the QT prolongation in HIV is related to 
drug used in treatment. Whether QT prolongation occurs 
primarily in HIV infection or as a manifestation of Autonomic 
dysfunction is not studied extensively except a few studies9.. 
We investigated the presence of cardiovascular autonomic 
dysfunction and its relation to QT prolongation in patients 
attending our clinics and admitted in wards at various stages of 
HIV infection. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Aim and Objectives 
 
AIMS AND OBJECTIVES 
 
1. To evaluate the presence and the extent of autonomic 
dysfunction in our hospital based population infected 
with HIV, compared with age and sex matched 
seronegative controls.  
2. To correlate the degree of dysfunction with the stage of 
HIV infection.  
3. To evaluate the presence of QT interval prolongation in 
HIV/AIDS patients.  
4. To investigative the relationship between autonomic 
dysfunction and QT prolongation. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature  
REVIEW OF LITERATURE 
        In spite of   the   insight    of   the 19th   century   
physiologist, Gaskell    (1886),   Bayliss      and      Starling   
(1899)67      into     the   autonomic nervous system it   was   not   
until   1925   that a    real understanding of the   clinical 
presentation   of   autonomic failure emerged. This work   came   
from   careful   clinical   investigations carried out by Bradbury 
and Eggleton. From our current vantage point it is remarkable 
how thoroughly these investigators were able to define their 
patient’s illness using a battery of bedside tests and laboratory 
investigations. Their contribution   remains   the single most 
intellectual achievement   in   our   understanding   of clinical 
autonomic failure.  
          However  major  advances   have   been   made since the 
early 1960’s that make it  necessary  to revive   our   thinking  
about   the mechanism of  autonomic  transmission  and  that  
have  significant implications  for  our  understanding  of  our  
disease  involving  the autonomic nervous disease and 
treatment. These advances include 
1. The discovery of non adrenergic, non cholinergic nerves 
and the later recognition of a multiplicity of neuro 
transmitters. E.g. Monoamines, purines and nitric oxide 
(Burnstock et al 196468,Burnstock and Milner 1992 ; 
Rand, 1992; Snidder, 1992 ) 
2. The concept of  neuromodulation   where   locally   
released agents can alter neuro transmission either by 
modulation of the  amount   of   transmitters   released   
(Kaczmarek   and Leviton 1987)69. 
3. Recognition of the importance of  the  sensory  motor  
nerve regulation of activity in many organs including  
lung,  heart, ganglion  and  many  blood  vessels (Maggi  
and  Meli  198870, Burnstock 1990)  
4. Recognition   of   the   intrinsic   ganglion   (e.g.  Heart   
and airways) containing integrated circuits capable of 
sustaining and modulating sophisticated  local  activities 
(Burnstock  et al, 1987)71. 
In addition to these concepts, the discovery by Furchgott 
that substances released from endothelial cells play an 
important role in addition to autonomic nerves in control of 
local blood flow (Furchgott and Zawadski 1983, Ralevic and 
Burnstock 1993) and the later identification of nitric oxide as 
the major endothelium derived relaxing factor (Palmer et al 
1988) shift the earlier emphasis on central control mechanisms, 
towards greater considerations of the sophisticated local 
peripheral control mechanisms. 
 HIV infection may be associated with abnormalities of 
Autonomic nervous system, particularly in advanced disease. 
The prevalence of Autonomic dysfunction in HIV varies from 5 
to 77% according to the definition10. These abnormalities were 
first brought to our attention by Craddock et al.5 who described 
syncopal reactions in AIDS patients who underwent fine needle 
aspiration of lung. These syncopal reactions were similar to 
typical vasovagal reactions and cardiorespiratory arrests 
following invasive procedures such as general and epidural 
anaesthesia. At the same period, various reports by of 
Dysautonomia in HIV was also published 3,4. 
These studies have been done mostly on white population, 
with a very few studies on non white population57,58 , despite 
the fact that there appears to be a significant difference in the 
autonomic function between two ethnic groups64.        
HIV AND PERIPHERAL NERVOUS SYSTEM 
         Neuromuscular disorder are   the   most   frequent   of   
the neurological   complications that occur in association with   
HIV infection   and   AIDS18,65. Inflammatory Demyelinating 
polyneuropathy (IDP)   may   be   the initial clinical 
manifestation occuring   at   the time of HIV seroconversion.   
The frequency   of distal symmetrical polyneuropathy (DSP) 
increases with decline in CD4 lymphocyte count and 
progression to AIDS66. In severely immunosuppressed patients 
(CD4 lymphocyte count <50 cells/mL), cytomegalovirus (CMV) 
may directly infect peripheral nerves,    presenting as   
progressive   polyradiculopathy   (PP)   or mononeuropathy 
multiplex (MM). 
 Peripheral   neurophaties   are   common and may 
complicate HIV infection at each of its    stages. Even during  
earliest state,  at or near  the  time of  seroconvertion,  a variety 
of neuropathies have been  described,   although   their  
incidence  is  low.  These include brachial – plexopathy,  
mononeuritis multiplex involving peripheral or  cravial neves  
and  polynueropathy13,14,15. 
1)  Distal Symmetrical Polyneuropathy  
Distal   symmetrical polyneuropathy  (DSP)   may   be    
clinically diagnosed   in   approximately  25%-30%   of  patients  
with   AIDS. The incidence and prevalence of DSP increases 
with the progressive immuno suppression that characterizes 
HIV-infection. The pathogenesis  of AIDS-associated  DSP is 
unknown. Numerous factors, including advanced age, 
nutritional status, chronic disease, low hemoglobin level, HIV 
itself, neurotoxic cytokines, HIV glycoprotein gp-120, and low 
CD4 counts, have been correlated with clinical and 
electrophysiological presence of peripheral nervous system 
(PNS) dysfunction . The dose-dependent neurotoxicity of these 
agents may be the result of interference with mitochondrial 
DNA synthesis, possibly associated with reduced levels of 
acetyl-carnitine . Patients with a previous history of neuropathy 
are more susceptible to the peripheral nerve toxicity of these 
agents. 
2)  Inflammatory Demyelinating   Polyneuropathy  
 Inflammatory demyelinating polyneuropathy (IDP) is an 
infrequent complication of HIV infection. It is clinically 
characterized by: (a) rapidly progressive muscle weakness 
involving two or more extremities, (b) generalized areflexia, (c) 
cranial nerve involvement (e.g. bilateral facial nerve paresis) . 
The acute form (AIDP) often occurs at the time of HIV 
seroconversion. The chronic form (CIDP) has a slower onset and 
gradual progression.  
3)  Progressive Polyradiculopathy 
Progressive polyradiculopathy (PP) occurs mainly in late 
stages of AIDS disease. Patients with PP generally present with 
radiating pain and paresthesias in the cauda equina 
distribution, rapidly progressive flaccid paraparesis, lower 
extremity areflexia, mild sensory loss, and sphincter 
dysfunction, often manifesting as urinary retention. In certain 
occasions a thoracic sensory level is present, suggesting 
concurrent myelopathy.                                                          
4)  Mononeuropathy Multiplex (MM)  
Patients with MM present with the acute onset of 
multifocal sensory or motor abnormalities in the distribution of 
cranial, mixed or cutaneous nerves. The form of 
mononeuropathy multiplex (MM) that occurs in relatively 
immunocompetent patients (CD4 lymphocyte counts greater 
than 200 cells/ml) is probably mediated by immune 
mechanisms.                                                          
5) Diffuse Infiltrative Lymphocytosis Syndrome  
Diffuse infiltrative lymphocytosis syndrome (DILS) is an 
unusual complication of HIV infection. It is characterized by 
CD8 hyperlymphocytosis that may involve peripheral nerve. 
DILS neuropathy may present as: symmetric or asymmetric 
sensorimotor neuropathy, distal sensory neuropathy, 
mononeuritis multiplex or demyelinating polyneuropathy. 
6)  Autonomic Neuropathy  
Several studies indicate that autonomic dysfunction, 
while often subclinical, is common in HIV infection, particularly 
in late stages of disease36. Autonomic neuropathy has been 
reported in AIDS patients often in conjunction with more 
general sensory polyneuropathy 12,26. Parasympathetic 
autonomic nervous system manifestations include resting 
tachycardia, impotence, and urinary dysfunction. Sympathetic 
autonomic nervous system dysfunction is characterized by 
orthostatic hypotension, syncope, diarrhea, and anhidrosis.  
Pathogenesis 
 Multiple factors may be involved in the mechanism of 
autonomic dysfunction, including central and peripheral 
nervous system pathology, dehydration, malnutrition and drugs 
(e.g. vincristine, tricyclic antidepressants, and pentamidine).  
 Apparently much more common is the development of 
demyclinating neuropathies during the asymptomatic or latent 
phase of HIV infection16,17. During the late stages the most 
common neuropathy is distal, predominantly sensory axonal 
neuropathy 16,18, 19. This is usually a late complication and 
occurs in the setting of AIDS. Characteristically sensory 
symptoms far exceed either sensory or motor dysfunction. The 
pathogenesis of this disorder is uncertain, but is related to 
cytotine dysregualtion, either alone or in concert with HIV- 
infection of nerve or dorsal root ganglia 19,20. 
 Several Antiretroviral drugs including didanosine (ddI), 
zalcitabine (ddC) and stavudine (d4T) ddI, 7have peripheral 
neuropathy as a major, dose-related side effect21,22,23. During 
late stages more serious infections neuropathies related to CMV 
are known to occur 12,24,25.  
 Prevalence of cardiac autonomic neuropathy and sensori 
motorneuropathy is about 15% each in HIV infection. The 
changes in CD4 count and respiratory arrhythmia also 
correlated significantly36. 
Autonomic nervous system 
          The autonomic nervous system conveys sensory 
impulses from the blood vessels, the heart and all of the organs 
in the chest, abdomen and pelvis through nerves to other parts 
of the brain (mainly the medulla, pons and hypothalamus). 
These impulses often do not reach our consciousness, but elicit 
largely automatic or reflex responses through the efferent 
autonomic nerves, thereby eliciting appropriate reactions of the 
heart, the vascular system, and all the organs of the body to 
variations in environmental temperature, posture, food intake, 
stressful experiences and other changes to which all individuals 
are exposed.   There are two major components of the 
autonomic nervous system, the sympathetic and the 
parasympathetic systems. The afferent nerves subserving both 
systems convey impulses from sensory organs, muscles, the 
circulatory system and all the organs of the body to the 
controlling centers in the medulla, pons and hypothalamus 
              The   impulses of  the  parasympathetic  system  
reach   the organs    of  the body  through the cranial nerves # 
3, 7, 9, & 10, and  some  sacral  nerves  to the eyes, the  
gastrointestinal  system,  and other  organs.  The   sympathetic   
nerves   reach  their   end-organs through  more devious 
pathways down the spinal cord to clusters of sympathetic  
nerve bodies (ganglia) alongside  the  spine where  the messages  
are relayed to other nerve bodies (or neurons) that travel to   a   
large  extent  with  the  blood vessels to all parts of the body. 
Through  these  nervous  pathways,  the  autonomic nerves   
convey stimuli  resulting in largely unconscious, reflex, bodily 
adjustments such  as  in the  size  of  the  pupil,  the  digestive  
functions  of  the stomach  and  intestines,  the  rate  and  
depth of respiration and dilatation  or  constriction  of  the  
blood vessels. The function of Autonomic nervous system in its 
regulation of the internal organs is to a high degree 
independent. When the autonomic nervous are interrupted, 
these organ continue to function, but they are no longer as 
effective in maintaining homeostasis and adapting to the 
demands of changing internal condition and external stress.  
Autonomic dysfunction 
 Impairment of Autonomic function may occur as part of 
the more common acute or chronic peripheral neuropathies  
(eg; Diabetic, alcoholic-nutritional, amyloid, Gullain-Barre 
syndrome, infections, heavy metal toxic and porrphyrias. 
Diseases of the peripheral nervous system may affect the 
circulation in two ways: the nerves from baroreceptors may be 
affected, interrupting normal homeostatic reflexes on the 
afferent side or post ganglionic efferent sympathetic fibres may 
be involved in the spinal nerves. The severity of the autonomic 
failure need not parallel the degree of motor weakness.  
 Autonomic dysfunction that accompanies diabetic 
neuropathy is the one that has extensively evaluated 27,28,29. 
 Duchen and Coworkers30 attributed the autonomic 
disorder to vacuolization of sympathetic ganglionic nervous, cell 
nervous and inflammation, loss of myelinated fibres in the vagi 
and white rami communicates, and loss of lateral horn cells in 
the spinal cord. They believe the later changes to be secondary. 
Clinical features of Autonomic Dysfunction can be divided 
as follows38 
(i) Cardiovascular symptoms: Postural hypotension, 
vertigo, syncope.  
(ii) Upper GI symptoms: Dysphagia, nausea, emesis, 
early satiety, bloating. 
(iii) Lower GI symptoms: Diarrhea, constipation 
involuntary loss of stools and incomplete 
evacuation.  
(iv) Urological symptoms: Dysuria, involuntary 
dribbling of urine, prolonged dribbling incomplete 
bladder emptying, impotence.  
(v) Others: Hypohydrosis, hyperhydrosis, Gustatory 
sweating.  
Physiological basis for testing Abnormalities of Autonomic 
Nervous System  
(i) Responses of Blood pressure and Heart Rate to changes 
imposture and breathing. 
 McLeod and Tuck31 state that in changing from 
recumbent to standing position a fall of more than 30mmHg 
systolic and 15 mmHg diastolic is abnormal; others give figures 
of 20 and 10mmHg. This excessive drop in Blood pressure 
indicates inadequate sympathetic vasoconstrictor activity. In 
response to the induced drop in blood pressure, the pulse rate 
normally increases: The failure of rise in heart rate in response 
to drop in blood pressure withstanding is a good indication of 
vagal nerve dysfunction34. In addition the pulse after rising 
initially in response to upright posture slows after about 15 
beats to reach a stable rate by the 30th beat. The ratio of R-R 
interval in the ECG, corresponding to the 30th and the 15th 
beats is an even more sensitive measure of the integrity of Vagal 
inhibition the sinus node. A ratio in nonelderly of less than 1.05 
is usually  abnormal, indicating loss of vagal tone34. 
 Another simple procedure for quantization of vagal 
function consists of measuring the variation in heart rate 
during deep breathing. Normally heart rate varies by as many 
as 15 beats per minute or even more, between expiration and 
inspiration; differences of less than 10 beats per minute may be 
abnormal. A yet more accurate test of vagal function is 
measurement of ratio of the longest R-R interval during forceful 
flow expiration to the shortest R-R interval during inspiration 
and deviation of expiration inspiration (E:I ratio) up to Age 40 
E:I of less than 1:2 as abnormal34. 
 In Valsalva maneuvers, the subject exhales into a 
manometer or against a closed glottis for 10-15 seconds. 
Creating a markedly positive intra thoracic pressure. The sharp 
reduction in blood pressure, due to reduction in venous return 
and cardiac output; the response as bar receptors into cause a 
reflex tachycardia and to a letter lesser extent peripheral 
vasoconstrictors. With the release of intrathoracic pressure, the 
venous return stroke volume and BP rise to higher than normal 
level, reflex parasympathetic influences than predominate and 
bradycardia results. Failure of the heart rate to risk during 
positive intra thoracic pressure indicates sympathetic 
dysfunction and failure of the heart rate to slow during Blood 
pressure overshoot indicates parasympathetic disturbance. In 
patients with autonomic failure, the fall in BP is not aborted 
during the last few seconds of increased intra thoracic pressure 
and there is no over shoot of BP when breath is released 34. 
Vasomotor reactions 
 Measurement of the skin temperature is a useful index of 
vasomotor function.  The integrity of sympathetic reflex arc 
which includes baroreceptors of the aorta and carotid sinus, 
their afferent pathways, the vasomotor centers and the 
sympathetic and parasympathetic outflow,  can be tested in a 
general way by the cold presser test,  grip test, mental 
arithmetic test and Valsalva maneuver. 
 Vasoconstriction induces an elevation in Blood pressure. 
Similarly the sustained isometric contraction of a group of 
muscles for say 5 minutes normally increases the heart rate 
and the systolic and diastolic pressure by at least 15mmHg 34. 
The response to both tests is impaired, particularly with lesion 
of the efferent fibers of the sympathetic reflex arc 34. 
Sudomotor function 
 Test for integrity of efferent sympathetic pathway. In 
sympathetic or galvanic skin- resistance test, a set of electrodes 
placed on the skin measures the resistance to passage of weak 
current in skin, the change in electric potential is the result of a 
ionic current within sweat glands. The response defends on 
sympathetic response to sweat glands (Gutrecht)32. A more 
quantitative and reproductive method is examination of 
postganglionic sudomotor function termed QSART, developed 
and studied extensively by Low33. It is essentially a test of distal 
sympathetic axonal integrity utilizing the local axon reflex.  
 
Autonomic dysfunction in HIV 
 Abnormalities in Autonomic nervous system occurring in 
HIV was first highlighted upon by Craddock et al.5 As 
mentioned previously the prevalence varies from 5-77% 
according to definition and patient selection10. 
 The cause of Autonomic dysfunction is unknown although 
HIV is neurotropic and has been isolated from peripheral 
nervous issues58 and also depletion of autonomic axons in 
small bowel mucosa has been documented in HIV infected 
patients61,62. Even though HIV is associated with various form 
of cardiac involvement, underlying myocardial disease is not-
implicated11. 
 In the pre-AIDS stage of infection autonomic function 
appears to be intact, yet alteration in baroreceptor / vagal 
function associated with depressed myocardial function may be 
an early warning signal reflecting cardiovascular processes 
potentially exacerbated by HIV spectrum35.   
 Patients with cardiac autonomic dysfunction where is 
severe stage compared to patients without autonomic 
dysfunction36. 
 
Treatment for Autonomic Dysfunction 
Consists of 
 Non-pharmacological measures like adequate intake of 
salt and fluids, in the range of 10 to 20g, of salt / day and 2-3 
litres of fluid / day. 
 Sleeping with the head end elevated will minimize the 
effects of supine nocturnal hypertension. Patients are advised 
to sit with legs dangling over the edge of the bed for several 
minutes before attempting to stand. Other maneuvers like leg–
crossing, contraction of leg muscles for 30 seconds. Such 
measures compress leg vein and increase systemic resistance. 
Compression stocking may be helpful. Anemia should be 
corrected. 
 If above measures are inadequate, drug treatment is 
necessary Midodrine is effective in dose of 5-10 mg orally tid, 
but some respond to best to decremental dosage- (treatment `15 
mg in morning, 10mg at noon at 5 mg at in a term non) 
Midodrine should not be taken after 6 pm, because it can 
aggravate supine hypertension, Pyridostigmine appears to 
improve orthostatic hypotension (OH). Fludrocortisone at dose 
0.1 mg/day and 0.3 mg bid orally will effectively reduce OH, but 
aggravate supine hypertension. Potassium supplements are 
necessary with chronic administration of fludrocortisone. 
Postprandial OH can be reduced by frequent small meals. 
Prostaglandin inhibitors taken with meals or midodrine can be 
used. Somatostatin analogue octreotide in dose of 25 µg bid to 
100-200 µg tid acts by inhibiting gastrointestinal peptides 
prevent the vasodilation and hypotension effects.  
 Zidovudine appears to have major beneficial effect in 
treatment of HIV associated autonomic dysfunction49,50 but 
some studies did not find any improvement in autonomic 
function with Zidovudine-treatment38. 
QTc – Interval and prolongation 
 QT interval taken from the onset of QRS complex to end of 
the ‘T’ wave and corrected for heart rate give the corrected QT 
interval (QTc). A QTc interval of more than 440 millisecond is 
considered prolonged 37.  
 QT interval prolongation is an irregularity of the electrical 
activity of the heart that places patients at risk for ventricular 
arrhythmias39. Patients with QT- prolongation are at high risk 
of serious ventricular arrhythmias usually, TdP, although 
monomorphic ventricular tachycardia may also develop41. 
 
QTc in HIV Disease spectrum 
 Patients with HIV disease have a significantly higher 
prevalence of QTc prolongation than a general hospital based 
population due to an acquired form of LQTS arising from HIV 
infection41. 
QTc prolongation and Drugs 
 Many of the drugs currently used in HIV positive patients, 
antibacterial, antifungal, psychotropic drugs and 
antihistamines have been associated with QT- prolongation42. 
Among the most important of risk factors is the concomitant 
use of drugs that share the CYP3A. Metabolic pathway. Since 
most protease inhibitors are potent inhibitors by CYP3A 
clinicians should be wary of this dangerous effect of HAART 
therapy. Pentamidine43, trimethoprim sulfamethoxazole44, 
Ciprofloxacin45, Clarithromycin41 are some of the drugs used in 
HIV infection to treat opportunistic infections which are 
associated with QTc prolongation. The drug  induced QT 
prolongation is usually caused by blockade  of human ether a-
go-go- related gene (HERG) potassium channels and it has been 
shown that the  HIV protease inhibitors (lopinavir, melfinavir, 
rifonavir and saquinavir) cause dose dependent block of HERG 
channels suggesting that protease inhibitors would predispose 
individuals to QT prolongation and TdP46. 
 Efavirenz, a novel non-nucleoside reverse transcriptase 
inhibitors, was also reported to cause QT- prolongation and 
severe ventricular arrythmias47. 
QTc – prolongation without previous recognized causes 
 Alteration in cardiac innervations have been described in 
HIV infection as mentioned previously and this has been 
evaluated as the cause of Autonomic-dysfunction12,26. 
 Villa et al. studied the role of Autonomic – neuropathy in 
causing QTc prolongation in HIV infected persons 9. 
 Patients with dilated cardiomyopathy have been shown to 
have increased QT duration, QT- dispersion and increased 
variability of QT dispersion, reflecting variations in T-wave 
morphology, the factors which might predispose them to the 
development of arrhythmic events 48. Kocheril et al.40 – found a 
significantly higher prevalence of QTc – prolongation in HIV 
infected patients than general- hospital based population and 
proposed that it may be due to an unrecognized acquired form 
of long QT syndrome.  
Treatment 
 This should be directed at removing precipitating factors 
ie : correcting metabolic abnormalities and removing drugs that 
have induced prolonged QT interval. In the setting of drug 
induced torsades de pointes atrial or ventricular over drive 
pacing and the administration of I.V magnesium have been 
useful in terminating and preventing arrythmias. Potassium 
channel – activating drugs such as Pinacidil and cromakalin 
may be useful in acquired forms of long QT- syndrome51. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and Methods 
MATERIALS AND METHODS 
STUDY POPULATION  
 A total of 216 patients were enrolled for the study from 
the population of HIV infected patients who attended the out 
patient clinics of the institute of Internal Medicine, the ART 
clinic and the VCTC center. The patient attending the ART 
clinic were enrolled before they were started on HAART therapy.  
 141 patients was excluded as per exclusion criteria. The 
remaining 75 patients were selected for the selected for the 
study who satisfied all the inclusion and exclusion criteria. 
Written consent was obtained from all patients participating in 
the study. 
 Age and sex matched controls were also studied for 
comparison and meaningful interpretation of data. The controls 
were recruited from outpatient’s clinic or were medical staff at 
the hospital. For HIV positive cases that were recruited from the 
wards, appropriate seronegative controls were recruited from 
the wards. All patients and controls were not from a single 
ethnic background.  
 
 Study duration 
  This study was conducted for a period of ten months from 
August 2005 to May 2006. 
Study Design  
 To evaluate the role of HIV infection as the cause of 
cardiac autonomic dysfunction and the prevalence QTc –
interval prolongation in patients  with autonomic dysfunction, a 
single centre matched care- control study design was chosen.  
Laboratory Methods  
 Testing for HIV 1 and 2 had seen performed on each 
patient using ELISA technique. For those with positive results 
on the first ELISA test a second more specific ELISA was used 
for confirmation. Western blot technique was not used for 
confirmation. All controls had been tested as HIV antibody 
negative by ELISA.  
 HIV positive patients were diagnosed as having AIDS, 
when these was AIDS defining opportunities infection or 
malignancy and a CD 4 count of less than 200 irrespective of 
the clinical stage of HIV infection52. HIV positive patients were 
also classified as having AIDS based on clinical features 
according to NACO guidelines. 
 All patients and control did not appear clinically 
dehydrated None of the subjects were underweight as assessed 
by BMI calculated using the formula. (Wt in kg / (ht in mt)2). 
Any subject treated for tuberculosis or diabetes mellitus, 
alcoholism, multiple system atrophy and other disorder known 
to affects the autonomic nervous system and drugs known to 
produce QT prolongation were excluded. Blood sugar, urea, 
creatinine, full blood count were checked to exclude anaemia, 
dehydration and adrenal insufficiency. Also serum calcium, 
which was corrected for serum albumin and serum potassium, 
was checked to eliminate metabolic causes of QT prolongation. 
CD4 count was performed for all HIV positive patients using 
flow cytometry. A routine X-ray chest and ECHO was not done 
for all patients.  
 Of the 75 HIV positive patients, only two patients had 
acquired HIV infection through blood transfusion and the rest 
73 patients had acquired through heterosexual intercourse. 
Thirty patients had asymptomatic HIV infection and forty 
patients had AIDS. 
METHODS  
 Detailed clinical history were taken from each patients 
and a completes review of their case notes performed. A 
complete clinical examination of the nervous system and 
cardiovascular system was done for each patient.  
Tests for autonomic functions  
 On the day of testing patients and controls were 
instructed not to ingest caffeine containing products. All 
recordings the done 5-8 hours post prandially. Blood pressure 
was recorded manually using sphygmomanometer (Life line- 
model max) and heart rate was measured in the ECG lab using 
semiautomatic, electrocardiograph machine (Model Alpha 99 
and BPL cardiart 6108). The time interval between two 
successive R waves and the QT interval was measured using a 
standard ruler. All the recordings were done with styli control 
set at 10mm/ mV and paper speed at 25 mm/sec. Five cardiac 
cycles were recorded per lead and a long lead II taken to serve 
as rhythm strip. 
 The methods used in testing autonomic function were 
similar to those used for assessing diabetic autonomic 
neuropathy by Ewing and Clarke53 and Bennett et al54. Al 
patients and controls were subjected to a battery of five tests as 
detailed below: 
Heart rate response to valsalva maneuver  
 The subject was seated quietly and them asked to blow 
into a mouth piece attached to a manometer, holding it at a 
pressure of 40 mm Hg for 15 seconds while a continuous 
electrocardiogram was recorded and the pressure is released 
while the ECG is still recorded for 20 beats. The maneuver was 
repeated three times with one minute interval in between and 
results were expressed as  
 Valsalva ratio =  longest R-R interval after the maneuver 
    ÷ shortest R- R interval being the 
    maneuver. 
The mean of the three-valsalva ratios was taken as the final 
value.  
Heart rate (R-R interval) variation during deep breathing. 
 The subject was asked to breathe deeply at six breaths / 
min (Five seconds “in” and five seconds “out”) for one minute. 
An ECG was recorded throughout the period of deep breathing 
and onset of each inspiration and expiration was worked on 
ECG paper. The maximum and minimum R-R intervals during 
each breathing cycle were measured with a ruler and converted 
to beats / min. The results of the rest were expressed as the 
mean of the difference between maximum and minimum heart 
rates for the six measured cycles in beats / min.  
Immediate heart rate response to standing  
 The test was performed with the subject lying quietly on a 
couch while the heart rate was recorded continuously on an 
electrocardiograph. The patient was then asked to stand 
unaided and the point at starting to stand was marked on ECG 
paper. The shortest R-R interval at or around the 15th beat and 
the longest R-R interval at around the 30th beat after starting to 
stand were measured with a ruler. The characteristic rate 
response was experienced by 30:15 ratios. 
Blood pressure response to standing 
 This test measured the subject’s blood pressure with a 
sphygmomanometer while he was lying quietly. Then he was 
made to stand up and the blood pressure again after one 
minute. The postural fall in blood pressure was taken as the 
difference between the systolic pressure lying and the systolic 
pressure standing. The test was in repeated three times and the 
mean systolic blood pressure was calculated.  
Blood pressure response to sustained hand grip  
 The blood pressure of the patient was taken three times 
before the maneuver. A modified sphygmomanometer was used 
to sustain handgrip. The patient was asked to grip the 
inflatable rubber and apply maximum voluntary pressure 
possible. A reading from the attached mercury manometer was 
taken during maximum voluntary contraction. There after, the 
patient was asked to maintain 30% of maximum voluntary 
contraction for as long as possible up to five minutes. Blood 
pressure was measured at one minute intervals during the 
handgrip. The result was expressed as the difference between 
the highest diastolic blood pressure during the handgrip 
exercise and the mean of the three diastolic blood pressure 
readings before the handgrip began.  
  
INTERPRETATION OF THE TEST WAS BASED ON THE 
WORKS OF EWING AND CLARKE53. 
Blood pressure test Heart rate variability test 
Score 
Response 
to 
standing 
Response 
to 
handgrip 
Valsalva 
ratio 
Deep 
breathing 
Response 
to 
standing 
0 ≤10 ≥ 16 > 1.21 ≥ 15 ≥ 1.04 
1 11 - 29 11 – 15 - 11 – 14 
1.01 – 
1.03 
2 > 30 ≤ 10 < 1.21 ≤ 10 ≤ 1.00 
 For grading of cardiovascular autonomic function, results 
are classified into normal, borderline and abnormal (scores 
0,1,2 respectively). An overall score ≤ 3 was considered normal, 
score > 3and < 8 were considered borderlines and score ≥ 8 
were judged was abnormal autonomic function56. 
 QT interval was taken from the onset of QRS complex to 
the end of T wave. QT was then corrected for heart rate using 
the Bazette’s formule37. 
 QTc interval = QT / (R – R) ½. A QTc interval more than 
440 
Millisecond is considered prolonged.                                                                     
 Inclusion criteria 
            1. Age more than 15 less than 60. 
            2. HIV positive patients confirmed by ELISA 
Exclusion criteria 
1. Age less than 15 and more than 60 
2. blood pressure more than 140/90mmHg 
3. Diabetes mellitus 
4. Any history suggestive of premorbid cardiac disease 
5. Alcoholism 
6. Pregnancy and puerperium  
7. Use of any drugs known to affect cardiovascular 
system 
8. Cigarette smoking in excess of five sticks per day. 
9. Patients who are underweight( BMI <19) 
10. HIV patients on HAART therapy, antituberculous 
drugs 
11. Patients with CNS lesions. 
STATISTICAL ANALYSIS 
 Statistical analysis was carried out for 111 patients (40 
AIDS 35 HIV positive without AIDS, 36 HIV negative) after 
categorizing each variable – Age, sex, BMI, autonomic function 
tests, autonomic dysfunction score, QTc interval and CD4 
count were analyzed. One way Analysis of variance (ANOVA) 
was performed for comparison of means of more than two 
groups. The significance of difference between two proportions 
was indicated by the chi-square (x2) statistic. The significance of 
difference in mean between two groups was calculated by 
student t-test. Variables were considered to be significant if 
(P<0.05). Intervariate analysis was done by using Pearson’s r- 
value correlation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observations and Results 
OBSERVATION AND RESULTS  
 TABLE - 1  
AGE VARIATION AMONG THE STUDY GROUPS 
 
SEX DISTRIBUTION IN STUDY GROUPS  
TABLE - 2 
 
Group  n Mean SD 
One way ANOVA  F-
test 
AIDS- 35 39.26 6.473 
AIDS+ 40 38.83 6.652 
Control 36 38.50 6.536 
Total 111 38.86 6.506 
F=0.12 
P=0.88 
Not significant 
Group Significance 
AIDS- AIDS+ Control  
n % n % n % 
Male 23 65.7 27 67.5 24 66.7 
Sex 
Female 12 34.3 13 32.5 12 33.3 
Group 
Total 
35 100.0 40 100.0 36 100.0 
χ2=0.03 
P=0.98 
Not 
significant 
 TABLE - 3 
BMI COMPARISON AMONG STUDY GROUPS 
 N Mean SD 
One way ANOVA   
F- test 
AIDS- 35 21.0869 0.66899 
AIDS+ 40 20.7290 0.59714 
Control 36 22.4514 1.10421 
Total 111 21.4005 1.09973 
F=46.1 
P=0.001 
Significant 
 
 
MEAN AND SD OF AUTONOMIC FUNCTION TESTS IN THE THREE 
GROUPS 
TABLE - 4 
BP HANDGRIP 
 N Mean SD 
One way ANOVA  
F-test 
AIDS- 35 12.2280 5.32830 
AIDS+ 40 11.8280 4.56186 
Control 36 17.0936 1.56770 
Total 111 13.66 5.32440 
F=18.28 
P=0.001 
Significant 
SD – Standard deviation 
ANOVA – Analysis of variance   
 
TABLE - 5 
BP STANDING 
 N Mean SD 
One way ANOVA   
F-test 
AIDS- 35 11.52 5.367 
AIDS+ 40 16.07 5.191 
Control 36 5.83 3.420 
Total 111 11.31 6.34 
F=43.96 
P=0.001 
Significant 
 
TABLE -6 
HR STANDING 
 N Mean SD 
One way ANOVA  
F-test 
AIDS- 35 1.1309 0.10617 
AIDS+ 40 1.0800 0.09457 
Control 36 1.2027 0.09420 
Total 111 1.1358 0.10992 
F=14.83 
P=0.001 
Significant 
SD – Standard deviation 
ANOVA – Analysis of variance   
 
TABLE – 7 
HR VALSALVA 
 
 
TABLE - 8 
HR DEEP BREATHING 
 N Mean SD 
One way ANOVA   
F-test 
AIDS- 35 12.2897 4.23885 
AIDS+ 40 11.1863 6.08651 
Control 36 16.7283 2.10688 
Total 111 13.3316 5.08876 
F=15.57 
P=0.001 
Significant 
SD – Standard deviation 
ANOVA – Analysis of variance   
 
 
 
N Mean SD 
One way ANOVA  F-
test 
AIDS- 35 1.2737 0.11914 
AIDS+ 40 1.1778 0.14223 
Control 36 1.3669 0.09609 
Total 111 1.2694 0.14378 
F=22.29 
P=0.001 
Significant 
TABLE - 9 
MEAN AUTONOMIC DYSFUNCTION SEVERITY SCORE 
 N Mean SD 
One way ANOVA   
F-test 
AIDS- 35 3.26 2.160 
AIDS+ 40 5.25 2.447 
Control 36 .36 0.867 
Total 111 3.04 2.819 
F=58.75 
P=0.001 
Significant 
 
FREQUENCY DISTRIBUTION OF NORMAL (0-3), 
BORDERLINE (4-7), ABNORMAL (8-10) 
Group 
AIDS- AIDS+ Control 
 
 
n % n % n % 
Significance 
0-3 23 65.7 12 30.0 36 
100.
0 
4-7 9 25.7 15 37.5   Score 
8-10 3 8.6 13 32.5   
Group Total 35 
100.
0 
4
0 
100.
0 
36 
100.
0 
χ2=42.35 
P=0.001 
Significant 
 
TABLE -10 
MEAN QTc IN THREE STUDY GROUPS  
 N Mean SD One way ANOVA  F-test 
AIDS- 35 42.1991 1.99971 
AIDS+ 40 43.5063 2.68179 
Control 36 41.3672 1.18973 
Total 111 42.4004 2.24571 
F=10.26 
P=0.001 
Significant 
 
 
FREQUENCY DISTRIBUTION QTc PROLONGATION IN 
THREE STUDY GROUPS  
Group 
AIDS- AIDS+ Control  
n % n % n % 
Significance 
<44 30 85.7% 22 55.0% 36 100.0% 
QTC 
>44 5 14.3% 18 45.0%   
Group 
Total 
35 100.0% 40 100.0% 36 100.0% 
χ2=24.64 
P=0.001 
Significant 
 
TABLE -11 
MEAN CD 4 COUNT  
 N Mean SD 
Student 
t-test 
AIDS- 35 398.17 106.552 
AIDS+ 40 157.70 91.273 
Total 75 269.92 155.543 
t=110.84 
P=0.001 
 
 
TABLE - 12 
CORRELATION BETWEEN AUTONOMIC NEUROPATHY (AN) 
AND QTc PROLONGATION IN TOTAL HIV POSITIVE CASE 
HIV + GROUP 
AN + AN -  
n % N % 
Significance 
QTc >44 23 62.16 - - x2 = 32.11 
QTc <44 14 37.83 38 100 P = 0.001 
Group 
Total  
37 100 38 100 Significant 
 
 
TABLE - 13 
CORRELATION BETWEEN AUTONOMIC NEUROPATHY (AN) 
AND QTc PROLONGATION IN AIDS GROUP. 
AIDS GROUP 
AN (s) AN (m) AN - 
 
Significant 
 
n % n % n %  
QTc> 49 7 53.84 11 73.33 - - x2  =15.27 
QTc<44 6 46.15 4 26.66 12 100 P=0.001 
Group 
Total 
1
3 
100 15 100 12 100 Significant 
 
TABLE - 14 
CORRELATION IN BETWEEN AUTONOMIC NEUROPATHY 
AND QTc PROLONGATION IN HIV + (AIDS-) GROUP. 
HIV + GROUP  
(AIDS NEGATIVE )  
AN (s) AN (m) AN - 
 
Significant 
 
n % n % n %  
QTc> 44 1 33.3
3 
4 50 - - x2  =13.10 
QTc<44 2 66.6
6 
4 50 24 100 P=0.001 
Group 
total 
3 100 8 100 24 100 Significant 
 
TABLE – 15 
CORRELATIONS BETWEEN THE QTc PRLONGATION AND 
AUTONOMIC DYSFUNCTION SCORE USING PEARSON 
CORRELATION 
   Score CD 4 QTC 
Pearson 
Correlation 
1 .202(*) 
.638(**
) 
Sig. (2-tailed) 0.00 .033 .000 
 
Score 
N 111 111 111 
Pearson 
Correlation 
0.202(*) 1 -.011 
Sig. (2-tailed) 0.033 . .906 
 
CD 4 
N 111 111 111 
Pearson 
Correlation 
0.638(**) -.011 1 
Sig. (2-tailed) 0.000 0.906 . 
 
QTC 
N 111 111 111 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
-1 to +1 
Correlation denoted by r  
Pearson correlation coefficient 
0-0.2   Poor Correlation 
0.2-0.4      Fair 
0.4-0.6       Moderate 
0.6-0.8     Good 
0.8-1.0       V. Good 
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A total of 111 cases were studied, 40, 35 and 36 for AIDS, HIV 
positive asymptomatic and HIB negative groups respectively. 
The mean age for the AIDS groups was 38.83, HIV positive 
(without AIDS) was 39.26 and HIV negative group was 38.56 
(P=0.88). The percentage of females in the AIDS, HIV positive 
and HIV negative group were 32.5%, 34.3% and 33.3% 
(P=0.98). This shows that cases and controls were age and sex 
matched. The mean BMI in the three groups where AIDS 
(20.72), HIV+ (21.08) and HIV – (22.45). Of the 75 HIV the 
positive patients 40 patients were in stage 4 and 23 patients in 
stage 3, 12 patients in stage 2. 
 Only 20 patients had symptoms of peripheral neuropathy, 
of which 10 patients were with borderline autonomic 
dysfunction and 5 patients had severe autonomic dysfunction. 
Symptoms of autonomic dysfunction were present in only 18 
cases out of 75 HIV positive patients. 14 patients belonged to 
the AIDS group and 4 patients belonged to the HIV positive 
(without AIDS) group. The symptoms of autonomic dysfunction 
correlated with severe autonomic dysfunction only in 8 patients 
and 5 patients had moderate autonomic dysfunction.  
Tests for autonomic functions  
 The study showed statistical significance for all the tests 
of autonomic dysfunction between the cases and control 
groups, as all the tests had P values of less than 0.05. 
 The mean score (± 2 S.D) for the 3 groups where AIDS 
groups 5.25 ± 2.44, HIV positive group 3.26 ± 2.16 and the HIV 
group 0.36 ± 0.86 and (P=0.001) shows that the autonomic 
dysfunction is significantly different between the three groups. 
Thirteen patients in AIDS group have severe autonomic 
dysfunction (32%) compared to three in HIV positive group 
(80%). Also 15 patients in AIDS group (37.5%) had borderline 
dysfunction compared to 9 patients in HIV positive group (26%). 
This finding showed a significance of (P=0.01). If borderline 
dysfunction was also taken into account 37 patients (almost 
54%) had evidence of autonomic dysfunction. 
 HR response to deep breathing was the most frequently 
abnormal (30 patients) followed by HR response to valsalva and 
BP response to hand grip (29 patients). The HR response to 
standing was the least abnormal (5 patients). In BP response to 
standing even though none of the patients had systolic blood 
pressure of more than 30 mm Hg, patients shows significant 
difference between the groups (P=0.001). 
QTc prolongation 
 Totally 23 out of 37 patients with autonomic neuropathy 
(AN) had QTc prolongation.  
 QTc prolongation was significantly different in the 3 
groups (P=0.001) with 18 patients having prolonged QTc in 
AIDS group as compared to 5 patients to HIV positive (without 
AIDS) group.  
 The QTc prolongation was significantly different in cases 
with AIDS (AN) (combined severe and moderate autonomic 
dysfunction) compared to cases without autonomic dysfunction 
(AN-) (P=0.001 x2 = 15.27. Similarly QTc was prolonged in HIV 
positive (AN+) when compared to QTc in HIV positive (AN-) 
group (P=0.001 x2 = 13.10). 
 When comparing the autonomic function severity score 
and QTc, there was a highly significant positive correlation. 
Hence when the QTc interval prolongs the is also a increasing 
in the severity score.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
DISCUSSION 
 The results of this study on native Indian population 
illustrate the fact that cardiac autonomic dysfunction is 
common in HIV– infected patients of the sub – continent and 
that autonomic function deteriorates with progression to AIDS. 
Similar findings have been reported in previous studies36,38,57. 
This study demonstrated significant abnormities is autonomic 
function using basic cardiovascular autonomic reflex tests, 
which have well been validated 54,55. 
 Autonomic abnormalities were more readily apparent in 
tests for heart rate variation to deep breathing and valsalva 
ratio. In our study 30 patients had abnormal HR response to 
deep breathing followed by 29 patients who had abnormal blood 
pressure response to hand – grip land HR response to valsalva 
maneuver. Heart rate response to standing was least significant 
with only 5 patients having abnormal response. 
 The most pronounced abnormalities were found in 
patients  with AIDS, but there was an trend of worsening 
autonomic function with progression of the disease as 
evidenced by the fact that the incidence of automatic 
dysfunction was 34% in HIV positive  cases and also the mean 
and were increases with the stage.  
 All the tests for autonomic dysfunction showed statistical 
significance (P=0.005). This is in contrast to the study by  
Rogstad et al.56  which showed significant differences between 
AIDS patients and control for supine heart rate, valsalva ratio 
heart rate changes with cold phase test, but no significant 
difference  in blood pressure and difference in heart rate to 
deep breathing, though there was a tread for worsening 
autonomic function with progression to AIDS. Divine 
Nizubontane et al57 who studied HIV infected African patients 
showed significant difference in tests for blood pressure 
variability and valsava ratio but no significance heart rate 
response to deep breathing and standing. This divergence of 
results is probably related to difference in design, sample size, 
patient selection and grading of autonomic function test. 
Similar to both the studies this study showed increasing 
autonomic tester of were abnormal, suggesting that autonomic 
neuropathy could be an early indicator of HIV related 
neurological involvement.  
 A prolonged QTc was present in 5 out of 35 (14.3%) HIV 
positive patients and 18 out of 40 in the AIDS group (45%). This 
shows that the prevalence of QTc prolongation increases when 
the patients move in the disease spectrum from HIV infection to 
AIDS, showing a probable role of disease process in the 
causation of prolonged QTc interval. After adjusting for the 
electrolytes, and known cause of QTc prolongation, QTc still 
differed significantly among the three groups (P = 0.001). QTc 
prolongation was significantly different in cases with AIDS 
(AN+) compared to AIDS (AN-) QTc prolongation was also 
significantly different in cases with HIV positive (AN+) when 
compared to HIV negative (AN-). Like wise a significant 
correlation was observed between autonomic function scores 
and QTc interval prolongation.  
 Villa et al9 studied 57 HIV positive and 23 HIV negative 
subjects for the effect of alteration in cardiac innervations on 
QT- interval prolongation. 37 patients had autonomic 
neuropathy and QTc was prolonged in 24 out of 37 patients 
(64.8 %) with autonomic neuropathy and in 5 out of 20 HIV 
positive ( with out autonomic neuropathy ) patients, which has 
a sensitivity of 65 % and specificity of 75 %. This result is 
comparable to results obtained in our study. 
  In our study the abnormalities of autonomic function did 
not correlate with the patients having symptoms and clinical 
features of peripheral neuropathy except in 5 cases with AIDS. 
Similarly only 8 patients had symptoms of autonomic 
dysfunctions. Nerve conduction studies were not performed to 
confirm these findings.  
 Previous clinical studies have shown both positive and 
negative results. Freeman et al36 demonstrated significant 
abnormalities in autonomic function   between 22 controls and 
26 HIV positive patients.  
 Scott et al59 carried out sequential autonomic tests on 22 
patients, but found evidence of autonomic abnormalities in only 
one subject who also had AIDS related dementia. Villa et al 
studied 10 male and 5 female drug addicts, 10 of whom were 
HIV positive. They measured the R- R interval vaccination to 
deep breathing and found that two autonomic neuropathy and 
QTc was prolonged in 24 out of 37(64.8%) patients with 
autonomic neuropathy and in 5 out of 20 HIV positive / AN – 
patients (sensitivity 65%, specificity 75%), which is comparable  
to the results obtained in my study. 
 Kocheril et al40 evaluated the etiology of LQTS in HIV 
infection. They observed a 7.0% prevalence of QT prolongation 
among non – HIV injected patients who served as controls. This 
was however much lower than 29% prevalence among 
hospitalized patients with HIV during the same period (P=0.002) 
is the absence of a known cause.  
 Even though is our study the QTc prolongation was 
significantly different in cases with autonomic neuropathy 
compared to cases without autonomic neuropathy, a higher 
incidence was found in patients with moderate autonomic 
dysfunction (61%) compared to patients with severe autonomic 
dysfunction (39%) in the AIDS groups. Probably some other 
factors also played a role in QT prolongation in these patients, 
which has to be evaluated only in further studies.  
 A routine ECHO or a cardiac muscle biopsy was not done 
in the study and hence a myocardial disease a cardiomyopathy 
could not be ruled out. Patients with dilated cardiomyopathy 
have been shown to have increased. QT interval duration 
(Alonso et al)48,  but in our study we have excluded patients 
with history suggestive of cardiac dysfunction. 
 There were certain limitations in this study:  
Nerves techniques for measuring autonomic functions like the 
computer aided power spectral analysis of heart – rate 
variability (HRV) could not be done because of limitations is 
resources and cost. A routine nerve conduction study was not 
done to assess the incidence of peripheral neuropathy in these 
patients. There was no facility for measuring serum 
magnesium. No Holter monitoring facility was available to 
assess the risk of ventricular tachycardia in patients with QTc 
prolongation. It was also not possible to do chromosomal 
studies to rule out the rate possibility of congenital LQTS. 
 The findings of autonomic dysfunction and QTc interval 
prolongation in HIV – infected subjects and AIDS patients 
portends danger. It means that apart from the other risk factors 
for cardiovascular disease, the danger of sudden death is real. 
In view of the risk of total cardio respiratory arrest, simple test 
such as the measurement of R- R interval variation could be 
useful in patients undergoing diagnostic invasive procedures, 
although it is unclear whether it would predict arrest. 
Zidovudine has been suggested in patients with HIV related 
neurological disorder63, which may be also appropriate for 
treatment of patients with autonomic dysfunction. This study 
also confirms that QTc is a reliable parameter indicative the 
presence of autonomic neuropathy and since many days used 
in treating HIV infection are also associated with peripheral 
neuropathy and QTc prolongation it is suggested that back 
ground QTc interval in individual patients be used to determine 
the type of drugs to be prescribed.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 CONCLUSION 
The following are conclusions from the study. 
1. Cardiac Autonomic dysfunction is common in HIV 
infected patients, the probability of which is 
significantly increased with progression to AIDS. 
2. The HIV positive asymptomatic subject have higher 
prevalence of QTc Prolongation compared to HIV 
negative subjective and as they moved to AIDS, the 
prevalence of QTc, prolongation increases. 
3. A significant correlation is present between autonomic 
dysfunction and QTc prolongation. This makes QTc 
measurement as a reliable parameter of indicating the 
presence of cardiac autonomic dysfunction, but further 
studies are necessary to firmly establish the 
relationship between automatic dysfunction and QTc / 
prolongation. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scope for Future Study 
SCOPE FOR FUTURE STUDIES 
 This study conducted in our hospital based population 
has significant observation and potential therapeutic 
implications. A few questions remain unanswered. The most 
basic one in why only a part of the HIV infected patients are 
prone to get autonomic dysfunction and QTc prolongation. The 
exact cause of autonomic dysfunction is patients with HIV 
disease spectrum has to be elucidated by further studies. 
 There is no longitudinal prospective study demonstrating 
the exact prognosis in patients with autonomic dysfunction. 
The natural history of cardiac autonomic dysfunction regarding 
the percentage of people developing complications (e.g., 
postural hypotension, sudden cardiac arrest etc) has to be 
demonstrated by further studies. 
 The appropriate time to initiate HAART therapy in 
patients with autonomic neuropathy has to be further analyzed. 
Further work also needs to be done on the regimen for the 
prevention and treatment of their complication. 
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Annexure  
PROFORMA 
• Name :   • Age     • Sex 
• Residence 
• I.P. No. 
• Marital Status: 
• Occupation 
• Smoking / Alcohol Status 
• History of Exposure 
Blood Transfusion, Surgeries, etc 
• Hist. Sugg. of Peripheral neuropathy : (Numbers, parenthesize, 
       pain etc) 
• Hist. Sugg. of Autonomic Neuropathy : (Postural 
giddiness,         urinary 
disturbance,         erectile 
dysfunction) 
• History Sugg. of Immuno  
Compromised state : Fever. 1 month / Weight loss 
      Chronic diarrhea / Recurrent 
       URI / skin & Oral 
problem 
• Examination:   Height:  Weight:  BMI: 
Vital Signs: Pulse:  BP:   RR:  
• Examination of Nervous system: 
• Examination of cardio vascular system: 
•  Clinical Stage of HIV: 
• CD 4 Count: 
TESTS FOR CARDIO VASCULAR AUTONOMIC FUNCTION 
 Test 1 Test 2 Test 3 Mean 
I  Valsalva Ratio     
ii  Deep Breathing Test     
iii  Heart rate  response 
 to standing 
    
iv  BP Response to 
 standing  
    
v  BP Response to 
 sustained Hand grip 
    
 
QT – Interval Test  QTc Mean 
At Rest    
Max Tachycardia    
Max Bradycardia    
• ECG: Axis:   PR:    ARS duration 
• Blood Sugar:   Sr. Na+:  Sr. Ca2+: 
• Sr. Albumin:      Sr. K+ 
 
Sl.No Name Age Sex BMI PN AN
HIV 
stage AIDS
BP 
handgrip
BP 
Standing
HR 
standing
HR 
valsalva
HR deep 
breathing Score QTc CD 4
1 Govindhan 38 M 20.86 - + 4 + 9.83 20 1.02 1.15 7.5 8 45.05 160
2 Kamala 34 F 19.56 - - 4 - 8 12.5 1.03 1.43 7.88 6 44.5 358
3 loganathan 49 M 21.32 + + 4 + 10.12 22.22 1 0.92 10 9 46.5 64
4 ganesan 35 M 20.55 - - 3 - 14 14 1.32 1.31 20 2 43.68 430
5 periyasamy 36 M 21.2 - - 3 - 12 21.5 1.3 1.07 14.38 5 41.87 454
6 kamalavathy 30 F 20.1 + - 4 + 10 18.88 1.04 1.36 5.06 5 42.34 130
7 Saravanan 40 M 21.25 + - 4 + 9.33 24.66 1.02 1.15 7.06 8 40.1 186
8 Murugan 32 M 20.48 - - 4 + 17 20.83 1.04 1.31 18.16 1 39.64 168
9 Jegan 42 M 21.42 - - 3 - 16.61 8.66 1.03 1.4 14.33 3 42 510
10 Manohar 36 M 21.65 + - 4 + 9.5 24 1.15 1.32 13.66 4 44 174
11 Geetha 30 F 19.78 - - 2 - 19.54 3.43 1.26 1.4 18.22 0 40.6 780
12 Selvarani 29 F 20.06 - - 4 + 5.8 22.22 1.01 1.12 18.83 5 45.5 120
13 Arrokiyam 34 M 21.23 - - 4 + 14.83 14.38 1.1 1.1 14 3 41.6 114
14 Marimuthu 31 M 21.45 - - 4 + 9 22.6 1.01 1.16 6.23 8 46.06 108
15 Baskar 39 M 20.1 - - 2 - 17.61 11.5 1.23 1.31 14.55 2 41 458
16 Sathish 37 M 19.85 - - 4 + 15.38 13.42 1.2 1.27 14 3 40.1 524
17 Kamalbasha 37 M 21.6 - - 3 - 4.16 12.56 0.92 1.12 12.66 8 42.55 320
18 Ravi 44 M 20.5 - + 3 - 11.82 6.16 1.14 0.95 11.58 4 41.3 360
19 Gurunath 39 M 20.8 + - 4 + 14.16 14.38 1.23 1.41 13.5 3 40.68 174
20 Pandian 47 M 21.34 - + 3 - 7.5 19.16 1.03 1.35 10.5 3 39.75 274
21 Gopi 36 M 21 - - 4 + 10.5 7.33 1.02 1.08 13.33 5 47.3 160
22 Kalaivani 30 F 20.3 + - 3 - 5.88 3.2 1.06 1.36 10.66 1 40.08 310
23 sindhu 35 F 21.6 + - 4 + 8.16 12.66 1.06 0.95 9.33 5 45.65 140
24 Milton 32 M 20.8 - 3 - 19 8.88 1.12 1.26 3.61 2 42.36 300
25 Mala 34 F 19.8 - + 4 + 8.28 18.95 1.02 1.15 7.88 8 43.2 154
26 Munusamy 39 M 21.46 + - 4 + 7.51 14.55 1.12 1.07 9.22 6 44.8 190
27 Palani 42 M 20.3 - - 4 + 16.16 12.33 1.06 1.35 14 2 40.24 186
28 Prema bai 39 F 19.78 - + 4 + 8.28 15.38 1.14 1.07 16.16 5 47.4 130
29 Krishnaveni 33 F 20.9 + - 3 - 7.51 13.68 1.23 1.27 13.06 4 40.16 404
30 Vijaykumar 31 M 21.5 + - 4 + 13.68 19.54 1.2 1 13.66 6 46.82 174
31 Karthik 35 M 20.35 + + 4 + 12.33 20.68 1 0.92 9.33 8 48.8 96
32 Dhanam 36 F 21.8 - - 4 + 18.23 4.53 1.16 1.41 7.5 1 40.1 130
33 Prabu 38 M 20.68 - + 4 + 3.52 18.95 1.02 1.07 14.31 8 43.36 88
34 Pannerselvam 40 M 21.44 - - 2 - 10.11 7 1.12 1.36 3.61 3 42.7 510
35 Backiyam 42 F 20.6 + - 4 + 15.38 14.55 1.2 1.31 5.06 4 39.56 180
36 Vijayan 41 M 19.88 - - 4 + 9.5 12.38 1.03 1.31 7.88 3 41.6 190
37 Chinnama 43 F 21.2 - - 3 - 17.38 13.42 1.14 1.27 11.58 2 39.8 280
38 Padmanaban 45 M 21.5 + - 3 - 5.8 19.58 1.01 1 14.33 8 42.88 340
MASTER CHART
Sl.No Name Age Sex BMI PN AN
HIV 
stage AIDS
BP 
handgrip
BP 
Standing
HR 
standing
HR 
valsalva
HR deep 
breathing Score QTc CD 4
MASTER CHART
39 Gomathi 38 F 20.76 - - 4 + 13.68 12.33 1.06 1.07 9.58 7 45.1 118
40 Raju 48 M 21.1 - + 4 + 4.87 21.42 0.85 0.92 7.5 9 45.64 74
41 Karunakaran 49 M 20.2 - - 4 + 2.6 15.4 1.03 1 9.5 8 42.66 106
42 Mariammal 30 F 21.32 - + 4 + 17.58 6.53 1.06 1.31 14.33 1 40.16 194
43 Babaraj 51 M 20.45 - - 2 - 13.68 8.66 1.12 1.27 14 2 41.3 460
44 Chitra 35 F 21.25 - + 3 - 8.28 12.33 1.21 1.36 6.11 5 42.46 350
45 Channa rao 55 M 21.18 - - 4 + 12.33 14.55 1.21 1.15 7.88 6 45.5 120
46 Somasekar 54 M 20.5 + - 4 + 5.2 12.38 1.01 1.07 9.33 8 43.46 110
47 Kondaiah 53 M 20.8 + - 3 - 1.38 7.66 1.08 1.36 13.66 1 41 400
48 Joseph 48 M 21.68 - + 3 - 13.52 13.33 1.12 1.23 14.55 3 43.6 324
49 Vijaya 41 F 21 - - 4 + 16.66 16.66 1.02 1.31 11.58 4 42.33 140
50 Govindhammal 32 F 22.3 - - 2 - 19.54 19.54 1.03 1.36 7.5 5 46.34 580
51 Gopi 30 M 20.3 - - 4 + 20 20 1.12 1.3 12.55 3 40.7 170
52 Vijayalakshmi 40 F 19.8 - + 4 + 22.22 22.22 1.03 1.12 5.06 8 46.42 160
53 Palaniammal 44 F 22.1 - - 2 - 4.52 4.53 1.31 1.4 18.83 0 41.18 454
54 Ravi 36 M 21.25 - - 3 - 20.06 20.06 1.03 1.07 5.58 8 47.08 330
55 Ramachandhar 37 M 20.46 + + 4 + 15.4 15.4 1.32 1.3 6.23 5 45.6 130
56 Mustafah 49 M 21.15 - + 2 + 9.5 7.51 1.31 1.36 14 2 39.53 520
57 Gajendhran 44 M 20.66 - + 4 + 7.28 17 1.02 1.15 3.61 8 43.3 104
58 Devika 43 F 20.76 - - 3 - 4.87 16.66 1.01 1.27 5.58 6 47.34 360
59 somaiya 50 M 21.43 + - 4 + 12.33 14.16 1.16 1.15 13.58 5 46.06 108
60 Kesarnath 50 M 22.1 - + 3 - 8.28 12.33 1.23 1.26 7.5 5 41.44 290
61 David 40 M 20.6 - - 4 + 14.5 23.51 1 1.1 4.06 8 45.84 94
62 Chellapan 35 M 21.56 - - 2 - 17.68 8.66 1.03 1.27 13.66 2 40.5 410
63 Sandhya 34 F 20.9 - + 4 + 13.68 14.53 1.1 1.28 14.33 3 41.3 160
64 Devaki 33 F 21.06 - - 2 - 18.16 6.42 1.12 1.3 15.06 1 39.85 520
65 Madhan 36 M 19.88 - - 4 + 12.58 7 1.03 1.25 8.61 4 45.65 126
66 Kumari 35 F 20.12 + + 4 + 16.23 12.66 1.02 1.31 40.06 3 40.6 134
67 Kandhasamy 40 M 21.8 - - 3 - 17.56 6.53 1.06 1.27 14.33 1 42.55 410
68 Selvi 32 F 20.67 - - 2 - 13.33 13.33 1.12 1.23 14.55 3 40.08 510
69 Pandian 47 M 20.43 - - 3 - 14 12.38 1.32 1.31 20 2 41 340
70 Kesavan 36 M 22 + - 3 - 12.16 21.5 1.3 1.07 14.38 5 44.68 480
71 Raman 33 M 21.9 - + 3 - 16.61 8.66 1.03 1.4 14.33 3 39.96 320
72 muniyandi 38 M 20.78 - - 2 - 13.83 14.38 1.1 1.27 14 3 42.36 440
73 Eswari 34 F 20.56 - - 2 - 10.11 4.53 1.16 1.31 11.58 3 43.78 320
74 paulraj 39 M 20.8 + - 3 - 5.88 3.2 1.06 1.36 10.66 1 43.1 290
75 Karuppaiah 48 M 21.6 - - 3 - 17.61 13.42 1.2 1.35 13.33 2 42.14 260
Sl.No Name Age Sex BMI PN AN HIV 
BP 
Handgrip
BP 
Standing
HR 
Standing
HR 
Valsalva
HR deep 
breathing Score QTc         
1 kandhan 32 1 22 - - - 17.38 0.6 1.12 1.3 12.66 0 40.1 0
2 kasthuri 33 2 20.16 - - - 16.16 1.12 1.06 1.36 14.55 0 41 0
3 sundharam 45 1 22.32 - - - 16.53 8.66 1.16 1.16 11.58 3 40.68 0
4 Munisamy 42 1 23.4 - - - 17 4.53 1.31 1.45 18.16 0 40.08 0
5 Hemalatha 36 2 23.2 - - - 16.73 5.53 1.21 1.31 18.83 0 42.36 0
6 Rajasekar 49 1 24 - - - 17.16 6.88 1.27 1.44 15.06 0 43.2 0
7 Rathnam 30 1 21.54 - - - 18.5 6.42 1.1 1.4 17 0 40.88 0
8 Lalitha 38 2 22.23 - - - 18.8 8.07 1.31 1.21 17.23 0 41.1 0
9 Hemnath 31 1 22.54 - - - 19.16 2.16 1.28 1.51 18.83 0 40.16 0
10 Aravindh 31 1 23.1 - - - 13.55 1.08 1.3 1.28 14 2 42.34 0
11 Kokila 32 2 22.8 - - - 17.61 3.23 1.21 1.31 16.73 0 42 0
12 Balamurugan 42 1 22.68 - - - 16.6 4.8 1.28 1.36 18.5 0 39.06 0
13 kannan 38 1 22 - - - 17.38 9.16 1.1 1.43 19.16 0 40.56 0
14 Rajashri 38 2 21.8 - - - 14.56 18.88 1.31 1.28 14.3 3 40.83 0
15 Vijayalakshmi 39 2 21.66 - - - 18.3 7.66 1.06 1.33 18.3 0 41.18 0
16 sivakumar 46 1 23.34 - - - 18.88 7 1.27 1.46 17.6 0 41.3 0
17 sukumar 51 1 22.41 - - - 16.73 8.06 1.12 1.27 17.33 0 42.66 0
18 Ramaraj 49 1 23.2 - - - 18.5 7.51 1.16 1.28 15.06 0 41.3 0
19 Manivel 38 1 22.18 - - - 17.68 6.66 1.12 1.4 18.16 0 40.5 0
20 Kavitha 34 2 22.43 - - - 16.73 4.53 1.087 1.23 16.16 0 40.06 0
21 Jayapal 51 1 23.8 - - - 17.16 2.42 1.21 1.35 17 0 39 0
22 Singaraj 32 1 22.18 - - - 16.88 1.2 1.27 1.31 17.23 0 39.8 0
23 Gagendren 45 1 21.4 - - - 13.68 1.8 1.12 1.45 13.66 2 42.53 0
24 Hemalatha 36 2 24.1 - - - 19.3 3.66 1.31 1.51 18.3 0 41.44 0
25 Lingaraj 39 1 23.8 - - - 17.16 6.53 1.33 1.43 19.55 0 42.3 0
26 Amaravathy 30 2 20.54 - - - 16.8 7 1.03 1.33 15.8 0 40.6 0
27 Iyyapan 44 1 22.6 - - - 19 7.5 1.36 1.57 17.38 0 43.68 0
28 Gomathy 33 2 21.9 - - - 18.88 8.66 1.21 1.28 16.73 0 42 0
29 Selvamani 50 1 24.14 - - - 17.38 9.51 1.1 1.36 18.83 0 41.6 0
30 Ramasamy 41 1 20.16 - - - 12.28 5.16 1.14 1.43 18.16 0 40.24 0
31 Radhika 40 2 22.34 - - - 16.73 6.73 1.08 1.51 17.58 2 42.88 0
32 Charles 31 1 24.32 - - - 16.79 6.66 1.31 1.28 14.33 0 43.1 0
33 Renumathy 35 2 22.12 - - - 16.66 4.16 1.23 1.38 19.16 0 42.36 0
34 Ranganathan 34 1 21.67 - - - 16.93 8.06 1.21 1.43 19.08 0 43.2 0
35 Elango 40 1 20.5 - - - 17.68 6.3 1.28 1.31 12.73 1 41.34 0
36 Murugan 31 1 23.69 - - - 18.12 2.16 1.27 1.51 17.5 0 41.8 0
HIV NEGATIVE CONTROLS
